Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM19 CAR-T in CD19+ Refractory or Relapsed B-ALL
NCT03173417Phase 2Completed
- Sponsor
- Immunochina Pharmaceuticals
- Start
- May 2017
- Primary completion
- May 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IM19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Immunochina Pharmaceuticals. Primary endpoint: Occurrence of study related adverse events at 2 years. Started May 2017; status: completed.
02
Drugs
IM19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03173417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173417.